Phase 4 N=1,291 Azithromycin - Ivermectin Mass Drug Administration for Skin Disease
Scabies · Yaws · Impetigo
Primary: Impetigo Prevalence at 12 Months — 79; 66; 20; 12 Cases of impetigo
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 3 N=375 Phase 3 Study to Evaluate WR 279,396 vs. Paromomycin Alone to Treat Cutaneous Leishmaniasis (in Tunisia)
Cutaneous Leishmaniasis
Primary: Final Clinical Cure Rate — 101; 102; 73 participants — p=0.0001
Phase 3 N=254 Multiple-Site Study to Evaluate the Therapeutic Equivalence of Permethrin Cream, 5% in the Treatment of Scabies
Scabies
Primary: Number of Patients in Each Treatment Group With Therapeutic Cure (Parasitological Cure Plus Clinical Cure) of Scabies — 83; 86 Participants
Phase 2 N=22 Dose-finding Study of Moxidectin for Treatment of Scabies
Scabies
Primary: Mortality Rate for Adult Scabies Mites — 2; 6; 8; 14 Adult mites
Phase 4 N=104 Comparing the Effectiveness of Individual vs. Household Treatment for Scabies in Lambaréné, Gabon
Scabies · Households
Primary: Number of Participants With Clinical Cure — 20; 33 Participants
Phase 3 N=118 Impact of Community Scabies Treatment on Head Lice Prevalence in the Solomon Islands
Scabies · Head Lice
Primary: Number of Participants With Headlice — 3 Participants
Phase 3 N=399 Phase 3 Study of Walter Reed (WR) 279,396 and Paromomycin Alone for the Treatment of Cutaneous Leishmaniasis in Panama
Cutaneous Leishmaniasis
Primary: Percent of Participants With Final Clinical Cure — 78.6; 77.8 percent of participants
Phase 2 N=30 Pharmacokinetics, Safety, and Efficacy Trial of WR 279,396 (Paromomycin + Gentamicin Topical Cream) and Paromomycin Topical Cream for the Treatment of Cutaneous Leishmaniasis in Panama
Leishmaniasis, Cutaneous
Primary: Number of Participants Who Obtained Final Clinical Cure of Index Lesion — 9; 13 Participants
Phase 2 N=92 Topical Treatment of Cutaneous Leishmaniasis With WR 279,396: A Phase 2 Study in the Old World
Cutaneous Leishmaniasis
Primary: Complete Clinical Response (CCR) of Lesion at Days 50, 100 and 180 (+7 Days) — 47; 30; 3; 12 Participants
N/A N=72 Disability and Quality of Life in Patients With Lymphatic Filariasis in Rural Southern India
Lymphatic Filariasis
Primary: Dermatology Life Quality Index (DLQI) Domain Scores — 3; 0; 1; 0 units on a scale
Phase 4 N=12 Post-treatment Effects of Ivermectin (IVM) or Diethylcarbamazine (DEC) in Loiasis
Loiasis
Primary: The Peak % of Baseline Eosinophil Count Measured During the First 7 Days Post-treatment. — 196; 165 percentage of baseline — p=0.68
N/A N=10 Dermatosis Papulosa Nigra
Facial Dermatoses · Seborrheic Keratoses
Primary: Percent Clearance of All Lesions — 88; 96; 92.5; 0 percentage of lesion clearance
N/A N=120 HIV And Parasitic Infection (HAPI) Study
HIV Coinfection
Primary: Number of Participants With and Without Intestinal Parasitic Infection — 36; 84 Participants
Phase 2 N=48 A Study to Evaluate the Efficacy and Tolerance of WR279,396 for Old World Cutaneous Leishmaniasis
Old World Cutaneous Leishmaniasis
Primary: Safety: Overview of Adverse Events — 16; 7; 0; 0 Participants
Phase 3 N=911 Clinical Endpoint Study of Ivermectin 0.5% Lotion
Head Lice
Primary: Percentage of Index Participants Who Were Considered a Treatment Success: PP Population — 90.9; 89.0 percentage of participants
Phase 3 N=140 Bio-equivalence Study Comparing Permethrin Cream, 5% With Elimite in Patients With Active Scabies.
Scabies
Primary: Proportion of Patients That Are Identified as Cured. — 68; 70 Participants
Phase 2 N=78 Dose Ranging Study of Ivermectin Treatment Conditioner in Subjects With Head Lice Infestation
Pediculus Humanus Capitis (Head Lice)
Primary: Percentage of Participants Who Were Lice-Free by Day 2 That Were Maintained Through Day 15 Post-treatment With Either Ivermectin or Placebo (Vehicle Control) — 56; 50…
N/A N=95 Defining Skin Immunity of a Bite of Key Insect Vectors in Humans
Zika · Dengue · Malaria
Primary: Number of Differentially Expressed Genes Between Bitten (Case) Versus Unbitten (Control) Skin for Each of the Three Vector Groups — 18; NA; 1; NA number of…
Phase 2 N=40 Effect of Albendazole Dose on Treatment of Lymphatic Filariasis
Lymphatic Filariasis
Primary: Microfilarial Counts at 1 Year — 0; 0; 0 MF/ML — p=<0.2
Phase 2 N=30 Rosacea and Ivermectin
Rosacea
Primary: Adherence - MEMs Cap — 21; 6; 15; 12 Participants
Phase 2 N=30 Safety, Efficacy and Pharmacokinetics (PK) Study of WR 279,396 Versus Paromomycin for Treatment of Cutaneous Leishmaniasis (Peru-PK)
Leishmaniasis, Cutaneous
Primary: Final Clinical Cure for Index Lesions — 11; 9 participants
Phase 2 N=58 A Study to Assess the Efficacy, Safety, and Tolerability of KPL-716 in Reducing Pruritus in Chronic Pruritic Diseases
Chronic Idiopathic Urticaria · Chronic Idiopathic Pruritus · Lichen Planus
Primary: Change From Baseline in Weekly Average WI-NRS at Week 8 — -4.3; -1.1; -4.3; -3.7 score on a scale — p=0.3980
Phase 4 N=24 Evaluating Treatment Resistant Dermatitis TaroIIR
Atopic Dermatitis · Psoriasis
Primary: Investigator Global Assessment- Atopic Dermatitis — 1.7; 1.5 units on a scale
N/A N=150 Evaluation of CL Detect™ Rapid Test to Detect Cutaneous Leishmaniasis
Skin Diseases
Primary: True Positive — 0 samples
Phase 4 N=41 Loiasis Cross-reactive Antigenemia and Treatment-related Adverse Events
Loiasis
Primary: Cross-reactive Antigenemia — 12 Participants
N/A N=87 Prevalence of Hookworm Infection and Community Preparedness for Hookworm Vaccine Trials in Endemic Areas of Brazil
Hookworm Infection
Primary: Size of Wheal Diameter at Site of Skin Test Application, Measured 15 Minutes After Injection — 3.5 cm
Phase 3 N=371 Phase III Clinical Study in Patients With Mild to Severe Scalp Psoriasis
Scalp Psoriasis
Primary: Proportion of Patients in Each Treatment Group Who Are Considered a Clinical Success — 49; 41 Participants — p=0.2961
N/A N=71 Xenodiagnosis After Antibiotic Treatment for Lyme Disease
Lyme Disease
Primary: Detection of Borrelia Burgdorferi in Ticks After Xenodiagnosis Procedure — 1; 0; 418; 319 Ticks
Phase 2 N=176 Albendazole Plus High Dose Ivermectin for Trichuriasis in Pediatric Patients
Trichuris Infection · Helminthiasis
Primary: Cure Rate — 1; 31; 6; 40 Participants
Phase 4 N=11 Evaluating the Efficacy and Tolerability of Application of Metaderm Product for the Treatment of Psoriasis
Psoriasis
Primary: Efficacy as Measured by the Mean Percentage Change in the Product of Static Physician Global Assessment (sPGA) and Body Surface Area (BSA). — 53.06; 65.6 percentage of…